Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer.

Tang D, Zhang Q, Zhao S, Wang J, Lu K, Song Y, Zhao L, Kang X, Wang J, Xu S, Tian L.

Clin Biochem. 2013 Jul;46(10-11):926-32. doi: 10.1016/j.clinbiochem.2013.01.027. Epub 2013 Feb 13.

PMID:
23415719
2.

Expression and correlation of matrix metalloproteinase-9 and heparanase in patients with breast cancer.

Tang D, Piao Y, Zhao S, Mu X, Li S, Ma W, Song Y, Wang J, Zhao W, Zhang Q.

Med Oncol. 2014 Jul;31(7):26. doi: 10.1007/s12032-014-0026-4. Epub 2014 May 27.

PMID:
24861922
3.

MiR-27 as a prognostic marker for breast cancer progression and patient survival.

Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, Yu F.

PLoS One. 2012;7(12):e51702. doi: 10.1371/journal.pone.0051702. Epub 2012 Dec 11.

4.

Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival.

Li Y, Hong F, Yu Z.

J Int Med Res. 2013 Jun;41(3):596-602. doi: 10.1177/0300060513485856. Epub 2013 May 21.

PMID:
23696595
5.

MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.

Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY.

RNA. 2008 Nov;14(11):2348-60. doi: 10.1261/rna.1034808. Epub 2008 Sep 23.

6.

High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.

Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H.

Breast Cancer Res Treat. 2009 Sep;117(1):131-40. doi: 10.1007/s10549-008-0219-7. Epub 2008 Oct 19.

PMID:
18932017
7.

MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.

Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY.

Breast Cancer Res Treat. 2012 Aug;134(3):1081-93. doi: 10.1007/s10549-012-2034-4. Epub 2012 Apr 4.

PMID:
22476851
8.

Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.

Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD.

Cancer Res. 2005 Jul 1;65(13):5778-84.

9.

Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer.

Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R.

Oncol Rep. 2012 Jun;27(6):1759-64. doi: 10.3892/or.2012.1709. Epub 2012 Mar 7.

PMID:
22407237
10.

microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin.

Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, Sun J, Tan FW, Ding DP, Xu XH, Zhou F, Tan XG, Hang J, Shi SS, Feng XL, He J.

J Biol Chem. 2011 Mar 25;286(12):10725-34. doi: 10.1074/jbc.M110.165654. Epub 2010 Dec 9.

11.

MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.

Song B, Wang C, Liu J, Wang X, Lv L, Wei L, Xie L, Zheng Y, Song X.

J Exp Clin Cancer Res. 2010 Mar 27;29:29. doi: 10.1186/1756-9966-29-29.

12.

Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion.

Wu ZS, Wang CQ, Xiang R, Liu X, Ye S, Yang XQ, Zhang GH, Xu XC, Zhu T, Wu Q.

BMC Cancer. 2012 Feb 1;12:51. doi: 10.1186/1471-2407-12-51.

13.

MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase.

Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D.

Cancer Res. 2011 Feb 1;71(3):645-54. doi: 10.1158/0008-5472.CAN-10-1910. Epub 2011 Jan 25.

14.

Clinical significance of microRNA-155 expression in human breast cancer.

Chen J, Wang BC, Tang JH.

J Surg Oncol. 2012 Sep 1;106(3):260-6. doi: 10.1002/jso.22153. Epub 2011 Nov 21.

PMID:
22105810
15.

The expression of heparanase and microRNA-1258 in human non-small cell lung cancer.

Liu H, Chen X, Gao W, Jiang G.

Tumour Biol. 2012 Oct;33(5):1327-34. doi: 10.1007/s13277-012-0380-9. Epub 2012 Apr 10.

PMID:
22488243
16.

Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients.

Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y, Wang YX, Qi P, Xu S.

Med Oncol. 2014 Nov;31(11):259. doi: 10.1007/s12032-014-0259-2. Epub 2014 Oct 1.

PMID:
25270284
17.

Down-regulated microRNA-124 expression as predictive biomarker and its prognostic significance with clinicopathological features in breast cancer patients.

Arabkheradmand A, Safari A, Seifoleslami M, Yahaghi E, Gity M.

Diagn Pathol. 2015 Sep 29;10:178. doi: 10.1186/s13000-015-0391-0. Retraction in: Diagn Pathol. 2016 Nov 2;11(1):122.

18.

Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.

Ota D, Mimori K, Yokobori T, Iwatsuki M, Kataoka A, Masuda N, Ishii H, Ohno S, Mori M.

Int J Oncol. 2011 Apr;38(4):955-62. doi: 10.3892/ijo.2011.926. Epub 2011 Jan 26.

PMID:
21271219
19.

Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.

Zhou T, Zhang G, Liu Z, Xia S, Tian H.

Int J Colorectal Dis. 2013 Jan;28(1):19-24. doi: 10.1007/s00384-012-1528-1. Epub 2012 Jul 7.

PMID:
22772712
20.

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.

Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ.

BMC Cancer. 2014 Jan 31;14:51. doi: 10.1186/1471-2407-14-51.

Supplemental Content

Support Center